Gilead inks deals with generics makers to supply COVID-19 therapy remdesivir for 127 countries

After scoring an early authorization for its COVID-19 therapy remdesivir, Gilead Sciences has been on the hunt for manufacturing partners to help boost production for the in-demand drug. Through a series of licensing agreements, Gilead has taken the first steps to build that network.